📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-12 15:37
103 analysed today
103
Today
136,623
All-time analysed
40,486
Positive
6,319
Negative
81,881
Neutral
7,869
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
11 announcements match the current filters (relevance ≥ 5).
Indo Us Biotech Q1 Results: Net Profit Drops 35% YoY to ₹3.04 Cr Despite 4% Revenue Growth
Indo Us Biotech reported a marginal 4.3% YoY revenue growth to ₹32.09 Cr for the quarter ended June 30, 2026. However, net profit saw a sharp decline of 35.4% YoY, falling to ₹3.04 Cr from ₹4.70 Cr in the year-ago period. This margin compression was primarily driven by a 128.6% spike in finance costs and higher overall operational expenses. Consequently, the basic EPS decreased to ₹1.51 from ₹2.35 in the corresponding quarter of the previous year.
Confidence: HIGH
What changedQ1 FY27 results show a significant 35% YoY drop in net profit despite a slight increase in top-line revenue.
Why it mattersThe sharp rise in finance costs and overall expense growth is outpacing revenue gains, which is a concern given the company's ₹37 Cr debt and the seasonal nature of the seed industry.
Revenue (Q1 FY27): ₹32.09 CrNet Profit (Q1 FY27): ₹3.04 CrYoY Profit Change: -35.4%Finance Costs: ₹60.19 lakhsQ1 Revenue vs FY26 Revenue: 29.05%
📅 Short termThe stock may face downward pressure in the short term due to the significant year-on-year decline in profitability and rising interest costs.
📈 Long termLong-term growth depends on the successful adoption of high-yield hybrid varieties and expansion into global markets; however, operational efficiency must improve to restore margins.
⚠ Risk flags
- Rising finance costs
- Margin compression
- Seasonal agricultural dependency
Key Highlights
Revenue from operations increased 4.3% YoY to ₹32.09 Cr from ₹30.77 Cr
Net profit declined 35.4% YoY to ₹3.04 Cr from ₹4.70 Cr
Finance costs surged 128.6% YoY to ₹60.19 lakhs from ₹26.33 lakhs
Total expenses rose to ₹30.03 Cr compared to ₹25.95 Cr in the previous year's quarter
Inventory changes of ₹12.16 Cr significantly impacted the quarterly cost structure
👀 What to Watch
Monitor the company's ability to manage rising finance costs and interest expenses. Watch for the impact of monsoon patterns on seed demand in the upcoming quarters, as the business is highly seasonal.
Indo Us Biotech Q1 Net Profit falls 35% YoY to ₹3.04 Cr despite 4% Revenue growth
Indo Us Biotech reported a marginal 4.3% YoY increase in revenue to ₹32.09 Cr for the quarter ended June 30, 2026. However, Net Profit declined significantly by 35.3% to ₹3.04 Cr, down from ₹4.70 Cr in the same period last year. The profitability was primarily impacted by a 128% surge in finance costs and higher production expenses, leading to a drop in EPS from ₹2.35 to ₹1.51.
Confidence: HIGH
What changedThe company released its Q1 FY27 financial results, showing a disconnect between top-line growth and bottom-line performance.
Why it mattersThe significant drop in profit despite higher sales indicates margin pressure from rising interest obligations and operational costs, which could affect the company's valuation if the trend continues.
Revenue (Q1 FY27): ₹32.09 CrNet Profit (Q1 FY27): ₹3.04 CrFinance Costs: ₹0.60 CrEPS (Q1 FY27): ₹1.51Debt-to-Equity Ratio: 0.40
📅 Short termThe stock may face downward pressure in the short term as the market reacts to the 35% decline in net profit and rising interest expenses.
📈 Long termLong-term performance depends on the company's R&D-led strategy for high-yield seeds and its ability to scale exports to offset domestic seasonal risks.
⚠ Risk flags
- Rising finance costs
- Margin compression
- Seasonal agricultural dependency
Key Highlights
Revenue from operations grew 4.3% YoY to ₹32.09 Cr from ₹30.77 Cr.
Net Profit fell 35.3% YoY to ₹3.04 Cr compared to ₹4.70 Cr in Q1 FY26.
Finance costs surged 128.6% to ₹0.60 Cr from ₹0.26 Cr in the year-ago quarter.
Total expenses rose to ₹30.03 Cr from ₹25.96 Cr, outpacing revenue growth.
Basic and Diluted EPS decreased to ₹1.51 from ₹2.35 YoY.
👀 What to Watch
Investors should monitor the company's ability to manage rising finance costs and production expenses. Watch for the impact of the monsoon season on seed demand in the upcoming Q2 results, as the company is highly sensitive to agricultural cycles.
Indo Us Biotech Appoints Bhagat & Associates as New Auditor Following Resignation
Indo Us Biotech Limited has announced a change in its statutory auditors effective June 15, 2026. M/s. Gautam N Associates resigned from the position, citing administrative and operational restructuring and the company's desire to appoint an auditor based near its registered office in Ahmedabad for better logistical coordination. Consequently, the Board has approved the appointment of M/s. Bhagat & Associates as the new Statutory Auditor, subject to shareholder approval. The outgoing auditor has confirmed there are no other material reasons for their resignation.
Key Highlights
M/s. Gautam N Associates resigned as Statutory Auditor effective June 15, 2026.
M/s. Bhagat & Associates (FRN: 101100W) appointed as the new auditor by the Board on June 16, 2026.
The change is driven by a need for logistical efficiency and local coordination in Ahmedabad.
Outgoing auditors confirmed no material concerns or disagreements with the management.
The new appointment is valid until the conclusion of the next General Meeting, pending shareholder approval.
👀 What to Watch
Investors should view this as a routine administrative change; however, they should review the next financial statement for any significant changes in accounting disclosures or audit notes.
Indo Us Biotech Appoints New Statutory and Internal Auditors for Operational Efficiency
Indo Us Biotech Limited has announced a complete change in its auditing team following a board meeting on June 16, 2026. M/s. Bhagat & Associates has been appointed as the new Statutory Auditor, replacing M/s. Gautam N Associates. Simultaneously, M/s. J. M. Raval & Co. has been appointed as the Internal Auditor for a five-year term (FY 2026-27 to 2030-31), replacing M/s. Raj Shah & Co. The company cited administrative restructuring and the need for a local Ahmedabad-based auditor to improve logistical efficiency as the primary reasons for these changes.
Key Highlights
Resignation of Statutory Auditor M/s. Gautam N Associates effective June 15, 2026.
Appointment of M/s. Bhagat & Associates (FRN: 101100W) as the new Statutory Auditor effective June 16, 2026.
Appointment of M/s. J. M. Raval & Co. as Internal Auditor for a 5-year tenure from FY 2026-27 to 2030-31.
Changes are driven by administrative restructuring and a preference for auditors located near the company's Ahmedabad headquarters.
The outgoing Statutory Auditor confirmed there are no concerns other than the company's desire for logistical optimization.
👀 What to Watch
Investors should view this as a routine administrative update; however, it is always prudent to monitor the first few financial statements under the new auditors for any significant changes in accounting treatments.
Indo Us Biotech Appoints New Statutory and Internal Auditors Effective June 2026
Indo Us Biotech Limited has announced a complete change in its auditing team, replacing both its Statutory and Internal Auditors. M/s. Bhagat & Associates has been appointed as the new Statutory Auditor, replacing M/s. Gautam N Associates, primarily to improve logistical efficiency with an Ahmedabad-based firm. Additionally, M/s. J. M. Raval & Co. has been appointed as the Internal Auditor for a five-year term starting from FY 2026-27. The outgoing auditors cited administrative restructuring and the company's desire for local coordination as the reasons for their resignation.
Key Highlights
M/s. Bhagat & Associates (FRN: 101100W) appointed as Statutory Auditor effective June 16, 2026, subject to shareholder approval.
M/s. Gautam N Associates resigned as Statutory Auditor effective June 15, 2026, citing administrative and operational restructuring.
M/s. J. M. Raval & Co. appointed as Internal Auditor for a fixed five-year term from FY 2026-27 to 2030-31.
The change facilitates closer local coordination as the new auditors are based near the company's registered office in Ahmedabad.
Outgoing auditors confirmed there are no professional concerns or disagreements leading to the resignation.
👀 What to Watch
Investors should monitor the upcoming shareholder meeting for the formal ratification of the new statutory auditor and ensure that the transition does not impact the timeliness of future financial disclosures.
Indo Us Biotech FY26 Net Profit Drops 19% to ₹13.12 Cr; Q4 Revenue Falls 57% YoY
Indo Us Biotech reported a 19.3% decline in annual net profit to ₹13.12 crore for FY26, despite a modest 6.5% increase in total revenue to ₹110.44 crore. The Q4 performance was significantly weak, with revenue plunging 57.7% YoY to ₹22.80 crore and net profit nearly halving to ₹1.97 crore. A major concern is the negative operating cash flow of ₹12.50 crore, driven by a ₹29.27 crore increase in inventory. Furthermore, the statutory auditor raised an 'Emphasis of Matter' regarding missing confirmations for trade balances and lack of documentation for retail cash sales.
Key Highlights
FY26 Net Profit fell to ₹13.12 crore from ₹16.27 crore in the previous year.
Q4 FY26 Revenue from operations dropped sharply to ₹22.80 crore vs ₹53.96 crore YoY.
Operating Cash Flow turned negative at -₹12.50 crore due to high inventory accumulation of ₹99.95 crore.
Inventory levels increased by 41% YoY, significantly impacting liquidity.
Auditors highlighted missing documentation for retail cash sales and unconfirmed trade balances in an Emphasis of Matter.
👀 What to Watch
Investors should exercise caution due to the sharp decline in quarterly performance and negative operating cash flows. The auditor's remarks regarding documentation for cash sales and unconfirmed balances are red flags that require further clarification from management.
Indo Us Biotech FY26 Net Profit Declines 19% to ₹13.12 Cr Despite 6.5% Revenue Growth
Indo Us Biotech reported a mixed set of results for FY26, with annual revenue growing 6.5% to ₹110.44 crore, while net profit fell 19.3% to ₹13.12 crore. The fourth quarter was particularly weak, with revenue dropping over 50% year-on-year to ₹22.80 crore. Profitability was pressured by rising production costs and employee expenses. Furthermore, the company reported a negative operating cash flow of ₹12.58 crore, primarily due to a significant increase in inventory levels which now stand at ₹99.96 crore.
Key Highlights
Annual Revenue from Operations increased to ₹110.44 crore in FY26 from ₹103.63 crore in FY25.
Net Profit for the full year FY26 decreased to ₹13.12 crore from ₹16.27 crore in FY25.
Q4 FY26 Revenue saw a sharp decline to ₹22.80 crore compared to ₹53.96 crore in the same quarter last year.
Inventory levels surged to ₹99.96 crore, leading to persistent negative cash flow from operations.
Auditors raised an 'Emphasis of Matter' regarding missing confirmations for trade receivables and lack of customer details for retail cash sales.
👀 What to Watch
Investors should exercise caution given the declining profit margins and the auditor's notes regarding internal controls over cash sales and receivables. The high inventory-to-sales ratio and negative cash flows are significant risks to monitor.
Indo Us Bio Tech Submits Q3 and Nine-Month Financial Results for FY 2025-26
Indo Us Bio Tech Limited has submitted its integrated financial filing for the quarter and nine-month period ending December 31, 2025. The submission follows the latest SEBI (LODR) Third Amendment Regulations of 2024 and specific circulars from December 2024 and January 2025. While the cover letter confirms the filing, the detailed financial performance metrics are contained within the attached report. This disclosure is a critical regulatory requirement for maintaining transparency with shareholders regarding the company's mid-fiscal year performance.
Key Highlights
Financial results submitted for the quarter ended December 31, 2025.
Financial results submitted for the nine-month period ended December 31, 2025.
Compliance maintained with SEBI Circular SEBI/HO/CFD/CFD-oD2/CIR/P/2024/185.
Adherence to BSE Circular 20250102-4 and NSE Circular NSE/CML/2025/02 dated January 2, 2025.
Full financial reports made available on the company's official website and exchange portals.
👀 What to Watch
Investors should download the full integrated filing from the BSE or NSE website to analyze specific revenue and profit growth figures. Compare the Q3 results against the previous year's corresponding quarter to gauge the company's current growth momentum.
Indo Us Biotech Approves Q3 FY26 Unaudited Financial Results
Indo Us Biotech Limited's Board of Directors met on January 21, 2026, to approve the unaudited financial results for the quarter ended December 31, 2025. The board also reviewed and approved the limited review reports provided by the company's auditors. The meeting was brief, lasting only 20 minutes, indicating a standard procedural approval of the quarterly figures. Investors should now analyze the detailed financial statements to assess the company's performance trajectory for the fiscal year.
Key Highlights
Board approved unaudited financial results for the quarter ended December 31, 2025
The board meeting was conducted on January 21, 2026, from 14:20 PM to 14:40 PM
Limited review reports from the statutory auditors were obtained and approved by the board
The filing was made in compliance with Regulation 30 of SEBI (LODR) Regulations, 2015
👀 What to Watch
Investors should review the detailed financial tables once published to evaluate revenue growth and margin stability. Compare the Q3 results with previous quarters to identify any seasonal trends in the biotech and seed business.
Indo Us Biotech Approves Q3 FY26 Unaudited Financial Results
Indo Us Biotech Limited's Board of Directors met on January 21, 2026, to approve the unaudited financial results for the quarter ended December 31, 2025. The board also reviewed and accepted the limited review reports provided by the statutory auditors. The meeting was conducted efficiently, lasting only 20 minutes from 14:20 to 14:40. This announcement confirms the completion of regulatory requirements for the third quarter of the fiscal year.
Key Highlights
Approval of unaudited financial results for the quarter ended December 31, 2025
Limited review reports from auditors were considered and approved by the board
Board meeting concluded within a 20-minute window (14:20 PM to 14:40 PM)
Compliance maintained under Regulation 30 of SEBI Listing Obligations
👀 What to Watch
Investors should examine the detailed financial statements once released to analyze revenue and margin trends compared to previous quarters.
Indo Us Biotech Receives ED Summons Under PMLA; Disclosure Delayed by Over One Month
Indo Us Biotech Limited has received a summons from the Directorate of Enforcement (ED), Raipur Zonal Office, under the Prevention of Money Laundering Act (PMLA), 2002. The summons, dated November 20, 2025, requires the Principal Officer to appear and produce specific documents for an ongoing investigation. Although received via email on November 27, 2025, the company only disclosed this to the exchanges on December 29, 2025. While the management claims no immediate material impact, the nature of the investigation and the significant delay in reporting are concerning for shareholders.
Key Highlights
Summons issued under Section 50(2) and 50(3) of the Prevention of Money Laundering Act (PMLA), 2002.
The summons (No. PMLA/SUMMON/RPZO/2025/1983) requires appearance of the Principal Officer and production of documents.
Significant disclosure delay: Summons received on Nov 27, 2025, but reported to exchanges only on Dec 29, 2025.
Company attributes the delay to internal review and legal assessment processes.
Management states there is no immediate material impact on financial or operational activities.
👀 What to Watch
Investors should exercise extreme caution as ED investigations under PMLA are serious and can lead to asset freezes or reputational damage. The delay in disclosure also raises corporate governance concerns that warrant close monitoring.
